Article
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2023
Sakai Tetsuya, Matsumoto Shingo, Ueda Yasuto, Shibata Yuji, Ikeda Takaya, Nakamura Atsushi, Kodani Masahiro, Ohashi Kadoaki, Furuya Naoki, Izumi Hiroki, Nosaki Kaname, Umemura Shigeki, Zenke Yoshitaka, Udagawa Hibiki, Sugiyama Eri, Yoh Kiyotaka, Goto Koichi
Abstract excerpt
INTRODUCTION: BRAF non-V600E mutations occur in 1% to 2% of NSCLCs. Because of their rarity, the clinical backgrounds and outcomes of cytotoxic chemotherapy or immunotherapy remain unclear, and no targeted therapies are approved for BRAF non-V600E-mutant NSCLC. METHODS: In this multi-institutional prospective lung cancer genomic screening project (LC-SCRUM-Asia), we evaluated the clinicogenomic characteristics...
Topics
Join the communities discussing this publication.
